Allergan acquired Kythera Biopharmaceuticals for approximately $2.1B in cash, gaining Kybella, the first non-surgical injectable treatment for moderate-to-severe submental fullness. Closed October 1, 2015.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Stalled
Assessment window: 5yr post-close.
Key facts
AnnouncedJun 17, 2015
ClosedOct 01, 2015
Deal value$2.1B
Deal typeAcquisition/Merger
Therapeutic areaSubmental fullness ('double chin') / aesthetic medicine
IndicationsSubmental fullness ('double chin') / aesthetic medicine
Key assetsKybella (deoxycholic acid injection)
MechanismCytolytic deoxycholic acid injectable for adipocyte lysis